Virtue Capital Management LLC Sells 769 Shares of Zoetis Inc. $ZTS

Virtue Capital Management LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 33.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,540 shares of the company’s stock after selling 769 shares during the quarter. Virtue Capital Management LLC’s holdings in Zoetis were worth $240,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in the business. Nova Wealth Management Inc. acquired a new position in Zoetis in the 1st quarter valued at approximately $25,000. 1248 Management LLC bought a new stake in shares of Zoetis in the first quarter worth $27,000. Saudi Central Bank acquired a new stake in Zoetis in the first quarter valued at $29,000. REAP Financial Group LLC raised its position in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC raised its position in Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.4%

Zoetis stock opened at $128.18 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $181.85. The firm has a market capitalization of $56.49 billion, a price-to-earnings ratio of 22.06, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The firm’s fifty day moving average price is $135.77 and its two-hundred day moving average price is $149.01.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the previous year, the company posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Analyst Ratings Changes

A number of equities research analysts have commented on ZTS shares. Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. KeyCorp initiated coverage on shares of Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating on the stock. UBS Group cut their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. lowered their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Moderate Buy” and an average target price of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.